PARP1 and cancer: This stratification yielded a trend towards diminished OS and PFS in both PTEN altered subgroups when compared to PTEN wildtype and contrasts with previous findings showing that cancers with PTEN loss exhibited increased sensitivity to PARP inhibitors16,17.